Most drugs are molecules. You synthesize a compound, you characterize it down to the last atom, you dose it, and it does one knowable thing. Siolta Therapeutics is making something harder to pin down: a living drug. STMC-103H, the company's lead program, is a defined consortium of bacteria - an actual community of microbes, grown, bottled, and given to a baby every day for the first year of life.
This is a genuinely strange proposition, and Siolta is refreshingly unembarrassed about it. The company was spun out of the University of California, San Francisco in 2016 by Nikole Kimes, a microbial ecologist who became CEO, and Susan Lynch, the UCSF scientist whose lab produced the underlying research, with Samir Kaul of Khosla Ventures rounding out the founding. The name "Siolta" is Gaelic for "seeds," which tells you the entire strategy before you read a single slide: don't attack the disease, plant the thing that prevents it.
The thing being planted is a healthy infant microbiome. There is a growing body of evidence that the microbes colonizing a newborn's gut help train the immune system, and that when that colonization goes sideways, the odds of atopic disease - eczema, food allergy, asthma - go up. Siolta's bet is that you can intervene in that narrow developmental window and change the trajectory. It is a preventive bet, which in a symptom-management industry is close to contrarian.
What separates Siolta from a decade of microbiome hype is that it did the boring, rigorous version. Rather than a vague probiotic or a fecal transplant of unknown composition, it built a proprietary human microbiota biobank, a screening pipeline to test candidate strains in the lab and in animals, and - critically - an oxygen-free manufacturing process, because the useful bugs are anaerobes that die on contact with air. Then it ran a real placebo-controlled trial with real endpoints.
"Siolta develops live biotherapeutics that target the core drivers of disease."
- The company mission, stated plainly
That trial, called ADORED, is the reason anyone outside the microbiome field is now paying attention. Siolta enrolled 238 newborns with a family history of allergic disease across 30 sites in the United States and Australia, and dosed them daily through their first year. In November 2025 the company reported that infants who completed a year of STMC-103H had a 64% lower risk of developing atopic dermatitis, along with a reported 77% reduction in food allergy risk versus placebo. Even the six-month completers showed a 53% reduction in eczema risk. The therapy was, in the company's telling, safe and well tolerated.
The appropriate response to numbers like these is enthusiasm tempered by statistics. A single Phase 2 result is a promising signal, not a settled fact; effect sizes can shrink in larger confirmatory trials, and the field has been burned before. But the direction is clear, the design was controlled, and the U.S. Food and Drug Administration thought enough of the program to grant it Fast Track Designation, the regulatory equivalent of "we're watching, keep going." The ADORED data was accepted as a late-breaking oral presentation at the 2026 American Academy of Allergy, Asthma and Immunology meeting in Philadelphia - the kind of stage where a field decides whether to believe you.
